Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug BGM-2121 enters first human tests

NCT ID NCT07346846

Recruiting now Disease control Sponsor: BioGate Precision Medicine Corp. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called BGM-2121 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug might help control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BGM-2121
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 35 people, focused on safety and dosing. The drug may not shrink tumors or may cause side effects. Many early-stage cancer drugs never make it to approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • National Cheng Kung University Hospital

    NOT_YET_RECRUITING

    Tainan, Taiwan

    Contact Email: •••••@•••••

  • National Taiwan University Hospital

    NOT_YET_RECRUITING

    Taipei, Taiwan

    Contact Email: •••••@•••••

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, Taiwan

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.